Bridging the gap between genetic variation and function in brain cells  

Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s, and understanding how they might impact specific cell functions.   

Email newsletter

News and blog updates

Sign up

By using lab-grown human brain cells, the team at the Wellcome Sanger Institute, Open Targets, and their collaborators, were able to show how genetic variants impact cell behaviour. Specifically, how genetic variations lead to differences in the ability of the brain immune cells to move and clear away biological debris.

In the research, published today (17 November) in Nature Genetics, the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. Overall, this research begins to show how to connect genetic risk variants with their downstream effects, the next step in understanding how genes impact health conditions.

Genome wide association studies (GWAS) scan genomes and highlight which differences, known as genetic variants, are more often found in patients with specific health conditions. They only signpost regions of the genome but they do not explain how those regions alter gene and cell function.

To bridge this gap, researchers developed a framework to map GWAS data to changes in gene expression and cell behaviour. For this, they used 261 human stem cell lines to derive brain cells known as microglia, which are a type of specialised immune cell that move around the brain and remove cellular debris or misfolded proteins. This is a process known as phagocytosis and is an important part of maintaining healthy neuronal function.

First, the team identified which genetic variants change the levels of different genes in microglia cells. Next, they asked if genetic regions that have been previously linked to Alzheimer’s, Parkinson’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) also modulate gene levels. They identified 79 regions; however, these links alone do not inform of the impact on cell function.

To further understand how these changes in gene expression alter cell behaviour, the researchers conducted laboratory tests on microglia, measuring the cells’ ability to move and undertake phagocytosis. Through these tests and computational modelling, they were able to map 34 genes to changes in cell behaviour. This highlighted disease-relevant variants at TREM2 that were linked to changes in phagocytosis.

To understand further how these genes impact behaviour of microglia, the team conducted CRISPR screens, knocking out 251 disease relevant genes. This also allowed them to show that the impact of the gene depends on the cellular context. For example, knocking out TREM2 increases phagocytosis in microglia but decreases it in macrophages, a different type of immune cell.

This research gives a scalable blueprint for studying brain immune cells, which are impossible to safely take samples of in living patients. It could also help find new pathways and drug targets from disease genetic data, giving insight into the cellular mechanisms that are linked to diseases.

“Brain conditions such as Alzheimer’s are incredibly complicated, and understanding how different parts of our genome are linked to these conditions could help us find new ways to identify or treat them. Identifying the associated part of the genome is the first step but it leaves a large translational gap, and our new research has found a way to bridge the gap between association and understanding the impact on the cell function. Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery.”

Dr Gosia Trynka, co-senior author at the Wellcome Sanger Institute and Science Director at Open Targets

“This ambitious study showcases the potential of iPSC-derived cells for genetic analysis, linking genetic variation to expression, cellular survival and function, and disease susceptibility. This approach is particularly valuable for difficult-to-access tissues such as the brain, allowing us to investigate genetic effects across multiple donors and stimulation conditions in microglia, which are challenging to obtain in sufficient numbers and under the right stimuli from primary human tissues. This framework has the potential to be extended to other diseases, tissues or cellular phenotypes, enabling research that would otherwise be extremely difficult to undertake.”

Dr Marta Perez-Alcantara, co-first author previously at the Wellcome Sanger Institute and Open Targets

“While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behaviour has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”

Dr Andrew Bassett, co-senior author at the Wellcome Sanger Institute and Open Targets

More information

Publication:

M. Perez-Alcantara, S. J. Washer, Y. Chen, et al. (2026) ‘Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk’. Nature Genetics. DOI: 10.1038/s41588-026-02843-0

Funding:

This work was conceived and funded by Open Targets. A full acknowledgement list can be found in the publication.